Mutational Landscape of Women with Metastatic Ovarian Cancer Before and During PARP Inhibitor Maintenance Treatment and Incidence of Therapy-related Hematological Neoplasms

What this Trial Is About

This research aims to understand the genetic changes in women with advanced ovarian cancer who are treated with PARP inhibitors, which are drugs targeting DNA repair defects in tumors. The study focuses on therapy-related acute myeloid leukemia and myelodysplasia as potential late complications from platinum-based chemotherapy and PARP inhibitor treatment. It investigates how pre-existing genetic mutations in blood cells might influence the development of these complications over time. Participants will provide samples of buccal cells, peripheral blood, and optionally bone marrow cells and biopsies for detailed genetic and cellular analyses. These analyses include identifying germline mutations, detecting clonal hematopoiesis of indeterminate potential (CHIP), and assessing mutations related to myeloid malignancies. Sampling occurs before starting PARP inhibitor treatment and every six months during treatment, with additional evaluations if blood abnormalities develop. Throughout the study, participants will have regular blood count monitoring monthly during PARP inhibitor maintenance. In case of blood abnormalities, treatment may be paused and further bone marrow and blood analyses performed. Researchers will assess the incidence of genetic events over eight years, monitor survival, and evaluate the impact of treatment on blood cell populations. The total participation duration spans several years with ongoing clinical and laboratory assessments.

Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors